Related Experiment Video
Updated: Jun 27, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Discovery of Benzophenanthridine Alkaloids from Zanthoxylum nitidum That Target the MDM2-p53 Axis in NSCLC
Nguyen Manh Cuong1, Elizaveta Fefilova2, Vu Thanh Loc1
1Institute of Chemistry, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Nghia Do, Hanoi 11353, Vietnam.
Abstract:
Background/Objectives: Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancers and is a leading cause of cancer-related deaths worldwide. Pharmacological targeting of the p53-MDM2 interaction to activate wild-type p53 is a promising strategy for treating NSCLC that retain functional p53 (approximately 50% of all cases). Methods: We screened 33 ethnomedicinal Vietnamese plant extracts for their anticancer effects using p53-expressing and p53-null NSCLC cell models, as well as two non-cancerous cell lines for control. We used an array of different experimental approaches including NMR spectroscopy; molecular docking; an MTT test; cell cycle analysis; apoptosis analysis; wound healing, migration, and invasion assays; Real-Time PCR; immunoblotting; and Seahorse energy profiling to characterize and study the effects of these bioactive compounds on NSCLC cells. Results: Ethanol extract of Zanthoxylum nitidum stems and twigs demonstrated potent and selective activity by inducing p53-dependent cell cycle arrest and apoptosis. Phytochemical analysis identified several benzophenanthridine alkaloids as active constituents. Molecular docking revealed their strong in silico binding to MDM2. Notably, nitidine was the most promising compound among the molecules tested. Unlike nutlin, but similar to SP141 (two well-known MDM2 inhibitors), nitidine strongly stabilized p53 while concomitantly attenuating MDM2 at the protein level. Surprisingly, this effect was p53-independent. Additionally, nitidine suppressed the EMT master regulator Snail, and hence disrupted cellular bioenergetics and inhibited migration and invasion of NSCLC cells. Conclusions: Our findings identify Z. nitidum and nitidine as promising sources for developing novel MDM2-targeting therapeutics against NSCLC irrespective of the p53 status.
Insights
Researchers identified Zanthoxylum nitidum extract and its compound nitidine as potential treatments for non-small cell lung cancer (NSCLC). These compounds target MDM2, offering a new therapeutic strategy for NSCLC, regardless of p53 status.
Area of Science:
- Natural product chemistry
- Cancer biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) is a major global cancer-related mortality cause.
- Targeting the p53-MDM2 interaction is a promising strategy for NSCLC with functional p53.
- Existing therapies have limitations, necessitating novel treatment approaches.
Purpose of the Study:
- To screen Vietnamese ethnomedicinal plants for anticancer activity against NSCLC.
- To identify bioactive compounds targeting the p53-MDM2 pathway.
- To evaluate the therapeutic potential of identified compounds in NSCLC treatment.
Main Methods:
- Screening of 33 Vietnamese plant extracts using NSCLC cell models (p53-expressing and p53-null).
- Utilized NMR spectroscopy, molecular docking, cell cycle analysis, apoptosis assays, migration/invasion assays, PCR, immunoblotting, and Seahorse energy profiling.
- Phytochemical analysis to identify active constituents from effective extracts.
Main Results:
- Zanthoxylum nitidum extract showed potent, selective activity, inducing p53-dependent cell cycle arrest and apoptosis.
- Benzophenanthridine alkaloids, particularly nitidine, were identified as active constituents with strong in silico binding to MDM2.
- Nitidine stabilized p53 and reduced MDM2 protein levels (p53-independent), suppressed Snail, disrupted cellular bioenergetics, and inhibited NSCLC cell migration and invasion.
Conclusions:
- Zanthoxylum nitidum and its compound nitidine are promising sources for novel NSCLC therapeutics.
- Nitidine demonstrates efficacy irrespective of p53 mutational status, offering a broad therapeutic window.
- These findings support the development of new MDM2-targeting drugs for NSCLC treatment.
Related Concept Videos
Abnormal Proliferation
Inhibition of Cdk Activity
Drugs that Destabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway
Drugs that Stabilize Microtubules
